Product Information
AZD4205 is a potent inhibitor of the JAK1 enzyme. It has been shown to reduce tumor cell growth and induce cancer cell death in vitro in a variety of human tumor cells. AZD4205 also inhibits the inflammatory response in animal models of bowel disease, such as ulcerative colitis. This drug is currently being evaluated in clinical trials for its effect on bowel diseases and cancer. In preclinical studies, AZD4205 has been shown to be well-tolerated with no dose-limiting toxicities reported. The most common adverse effects were diarrhea, nausea, vomiting, abdominal pain, decreased appetite, headache and dizziness. AZD4205 has been shown to be effective at doses as low as 0.5 mg/kg/day (0-2 times the effective dose).
Chemical properties
Technical inquiry about: 3D-BA177711 AZD4205
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
